U.S. Compounding Pharmacies Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Compounding Pharmacies Market 

5.1. COVID-19 Landscape: U.S. Compounding Pharmacies Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact:  Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8.  U.S. Compounding Pharmacies Market, By Pharmacy Type

8.1. U.S. Compounding Pharmacies Market, by Pharmacy Type, 2024-2033

8.1.1. 503A

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. 503B

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9.  U.S. Compounding Pharmacies Market, By Product

9.1. U.S. Compounding Pharmacies Market, by Product, 2024-2033

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Liquid Preparations

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Topical

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Rectal

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Ophthalmic

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.6. Nasal

9.1.6.1. Market Revenue and Forecast (2021-2033)

9.1.7. Otic

9.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 10.  U.S. Compounding Pharmacies Market, By Sterility

10.1. U.S. Compounding Pharmacies Market, by Sterility, 2024-2033

10.1.1. Sterile

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Non-Sterile

10.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 11.  U.S. Compounding Pharmacies Market, By Compounding Type

11.1. U.S. Compounding Pharmacies Market, by Compounding Type, 2024-2033

11.1.1. Pharmaceutical Ingredient Alteration (PIA)

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Pharmaceutical Dosage Alteration (PDA)

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Others

Chapter 12.  U.S. Compounding Pharmacies Market, By Therapeutic Area

12.1. U.S. Compounding Pharmacies Market, by Therapeutic Area, 2024-2033

12.1.1. Hormone replacement

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Pain management

12.1.2.1. Market Revenue and Forecast (2021-2033)

12.1.3. Dermatology

12.1.3.1. Market Revenue and Forecast (2021-2033)

12.1.4. Pediatrics

12.1.4.1. Market Revenue and Forecast (2021-2033)

12.1.5. Urology

12.1.5.1. Market Revenue and Forecast (2021-2033)

12.1.6. Others

12.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 13.  U.S. Compounding Pharmacies Market, By End-User

13.1. U.S. Compounding Pharmacies Market, by End-User, 2024-2033

13.1.1. Hospitals and Clinics

13.1.1.1. Market Revenue and Forecast (2021-2033)

13.1.2. Specialty Clinics

13.1.2.1. Market Revenue and Forecast (2021-2033)

13.1.3. Others

13.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 14.  U.S. Compounding Pharmacies Market, Regional Estimates and Trend Forecast

14.1. U.S.

14.1.1. Market Revenue and Forecast, by Pharmacy Type (2021-2033)

14.1.2. Market Revenue and Forecast, by Product (2021-2033)

14.1.3. Market Revenue and Forecast, by Sterility (2021-2033)

14.1.4. Market Revenue and Forecast, by Compounding Type (2021-2033)

14.1.5. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

14.1.6. Market Revenue and Forecast, by End-User (2021-2033)

Chapter 15. Company Profiles

15.1. Triangle compounding pharmacy

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Fagron

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. B. Braun melsungen ag

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Fresenius kabi ag

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Pencol Compounding Pharmacy

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. US Compounding Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Avella specialty pharmacy

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Institutional pharmacy solutions, llc

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Pharmedium services llc

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Vertisis custom pharmacy

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms